English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background  The surgical insult induces an inflammatory response that activates P38 MAP kinases and solid tumours can also release cytokines. Therfore inhibition of these pathways may reduce tumour growth We set out to examine the effects of P38-MAPK inhibition on apoptosis, proliferation, VEGF release and cell cycle effects  in-vitro  and on primary tumour growth  in-vivo .    Methods  4T-1 cells (2 × 10 5 cells/well) were incubated, in 24 well plates with control, 25, 50 or 100 ng/ml of SB-202190 for 24 hours. Cells were subsequently asessed for apoptosis, proliferation, VEGF release and cell cycle analysis. Balb-c mice each received 1 × 10 6  4T1 cells subcutaneously in the flank and were then randomised to receive control or SB202190 (2.5 μM/kg) by intraperitoneal injection daily. Tumour size was measured alternate days and at day 24 animals were sacrificed and serum VEGF assessed.    Results  P38-MAPK inhibition  in-vitro  resulted in a significant reduction in proliferation (75.2 ± 8.4% vs. 100 ± 4.3%, p < 0.05) and G 1  cell cycle phase(35.9 ± 1.1% vs. 32.5 ± 0.6%, p < 0.05) but no significant changes in apoptosis or VEGF levels.  In-vivo , P38-MAPK inhibition resulted in an increase in primary tumour growth (155.6 ± 34.9 vs. 86.7 ± 18.2 mm 3 , p < 0.05). P38-MAPK inhibition also lowered circulating VEGF levels but this difference was not significant (101.9 ± 27.1 ηg/ml compared to 158.6 ± 27.1 ηg/ml)    Conclusion  These findings demonstrate that P38-MAPK inhibition in-vitro reduces proliferation and G 1  cell cycle phase as well as promoting primary tumour growth in-vivo. These effects would appear to be independent of VEGF.

P38 MAP Kinase inhibition promotes primary tumour growth via VEGF independent mechanism